Table 3. In vitro inhibitory effects of selected compounds in non-tumoral cells.
| Antiproliferative activitya GI50 (μM) | ||||
|---|---|---|---|---|
| Comp | PBL(resting) | PBL(+Pha)b | Human fibroblasts | HUVEC |
| 10a | 1.5 ± 0.64 | 0.034 ± 0.007 | 5.8 ± 1.3 | 5.1 ± 0.43 |
| 10b | 34.8 ± 15.6 | 1.88 ± 0.71 | 30.5 ± 9.6 | n.d. |
| 10f | 1.4 ± 0.6 | 0.10 ± 0.03 | 9.8 ± 2.5 | n.d. |
| 10g | 0.98 ± 0.25 | 0.55 ± 0.11 | 7.4 ± 2.4 | 10.4 ± 3.5 |
| 10h | 1.0 ± 0.42 | 0.32 ± 0.03 | 3.7 ± 0.43 | 16.0 ± 6.6 |
| 10j | 2.0 ± 0.24 | 0.095 ± 0.021 | 14.3 ± 1.2 | n.d. |
| 10k | 2.1 ± 0.80 | 0.034 ± 0.007 | 3.2 ± 0.86 | n.d. |
| 10l | 3.8 ± 0.55 | 0.49 ± 0.15 | 9.6 ± 1.3 | 11.4 ± 5.9 |
| RSM932A | 1.1 ± 0.09 | 0.23 ± 0.05 | n.d | 0.46 ± 0.047 |
| MN58b | 2.0 ± 0.4 | 0.15 ± 0.05 | n.d. | 2.1 ± 0.58 |
aGI50 = Compound concentration required to inhibit tumor-cell proliferation by 50% Values are the mean ± SEM for three independent experiments. n.d. not determined.
bPha, Phytohematoagglutini.